BioNTech

51 articles with BioNTech

• BioNTech Announces Pricing of Initial Public Offering

  10/10/2019

  BioNTech SE announced the pricing of its initial public offering of 10,000,000 American Depositary Shares representing 10,000,000 ordinary shares at a public offering price of $15.00 per ADS, for gross proceeds of $150,000,000.

• BioNTech Announces Commencement of Initial Public Offering

  9/24/2019

  BioNTech SE announced that it has filed a registration statement on Form F-1 with the United States Securities and Exchange Commission to offer 13,200,000 American Depositary Shares representing its ordinary shares to the public.

• BioNTech Announces New Collaboration to Develop HIV and Tuberculosis Programs

  9/4/2019

  Bill & Melinda Gates Foundation invests $55 million in an infectious disease collaboration that could reach up to $100 million in total funding

• BioNTech Raises USD 325 Million in an Upsized Series B Financing to Further Advance Individualized Immuno-Oncology Pipeline

  7/9/2019

  One of the largest private EU biotech funding events expands global shareholder base

• 

  Despite IPO Rumors, BioNTech Closes Upsized Series B Worth $325 Million

  7/9/2019

  This makes it one of the biggest single private funding rounds for a biotechnology company in European history.

• Sugars that coat proteins are a possible drug target for pancreatitis

  6/20/2019

  Pancreatitis is an inflammation of the pancreas that accounts for 275,000 hospitalizations in the United States annually.

• 

  BioSpace Global Roundup, June 20

  6/20/2019

  Biotech and pharma companies from across Europe and Asia share company and pipeline updates.

• BioNTech and Genmab Initiate First-In-Human Phase I/IIa Trial of Bispecific Antibody DuoBody®-PD-L1x4-1BB in Solid Tumors

  6/17/2019

  BioNTech SE, a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and other serious diseases, announced that the first-in-human Phase I/IIa study with DuoBody-PD-L1x4-1BB has been initiated.

• 

  BioSpace's Global Biopharma Roundup: May 9

  5/9/2019

  Companies from across the globe provide updates to their pipelines and businesses, with news from BioNTech, Mologic, Akcea, RedHill, and more.
• 

  4 Biotech Companies List on the Nasdaq Today

  5/9/2019

  Four biotech companies began trading on the Nasdaq this morning. Here's a look at today’s launches and one rumored IPO.

• BioNTech Acquires MabVax Therapeutics’ Antibody Assets to Expand Portfolio

  5/8/2019

  BioNTech SE announced the acquisition of antibody assets and infrastructure from San Diego-based MabVax Therapeutics Holding, Inc., a clinical-stage oncology drug development company.

• 

  BioSpace's Global Biopharma Roundup: March 14

  3/14/2019

  In addition to the planned BioNTech IPO, many other pharma and biotech companies in Europe, Asia and elsewhere shared news for the week.
• 

  Germany’s BioNTech Taps Banks to Prepare for $800 Million IPO

  3/13/2019

  For BioNTech, the IPO will follow a funding round that brought about $270 million into the coffers of the privately-held company.
• 

  BioSpace's Global Biopharma Roundup: March 7

  3/7/2019

  Biotech and pharma companies from across the globe share data and news in a weekly roundup.
• 

  Moderna’s Not the Only One: A Look at the mRNA Market

  2/4/2019

  Messenger RNA (mRNA) is a family of RNA molecules that transport genetic information from DNA to the ribosome, where it specifies the amino acid sequence that creates proteins. In theory, by coding your own mRNA, it should be possible to insert it into the cells and turn them into protein factori...

• BioNTech to Acquire Antibody Generation Unit of MAB Discovery

  1/23/2019

  BioNTech AG and MAB Discovery GmbH announced that both partners have entered into a definitive agreement under which BioNTech will acquire MAB Discovery’s operational antibody generation unit.

• 

  BioNTech Buys MAB Discovery’s Antibody Generation Unit

  1/23/2019

  BioNTech AG inked a deal with Munich, Germany’s MAB Discovery GmbH to acquire MAB’s operational antibody generation unit. No financial details were disclosed.
• 

  BioNTech Teams up With Sanofi to Target Solid Tumors in $91.5 Million Deal

  1/4/2019

  Days ahead of the J.P. Morgan Healthcare Conference, Germany-based BioNTech extended its three-year-old collaboration with Sanofi as the companies look to co-develop the first cancer immunotherapy candidate for solid tumors.

• BioNTech: MammaTyper® Validated as Predictor for Response After Neoadjuvant Chemotherapy (NACT) in Patients with Early Breast Cancer (BC)

  11/28/2018

  New results from a clinical performance evaluation study of the CE-marked IVD MammaTyper® which were presented at the European Society for Medical Oncology (ESMO) in Munich in October.(1,2)

• BioNTech and the University of Pennsylvania Enter into Strategic Research Collaboration to Develop mRNA Vaccine Candidates Against Various Infectious Diseases

  11/5/2018

  ​New research program between BioNTech and the University of Pennsylvania